Compare LTRN & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LTRN | GDTC |
|---|---|---|
| Founded | 2013 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.3M | 15.5M |
| IPO Year | 2020 | 2023 |
| Metric | LTRN | GDTC |
|---|---|---|
| Price | $3.59 | $1.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | ★ 52.7K | 38.4K |
| Earning Date | 11-12-2025 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $573,193.00 |
| Revenue This Year | N/A | $5.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 63.03 |
| 52 Week Low | $2.55 | $0.89 |
| 52 Week High | $6.12 | $3.68 |
| Indicator | LTRN | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 54.64 | 26.33 |
| Support Level | $3.22 | $0.89 |
| Resistance Level | $3.56 | $1.39 |
| Average True Range (ATR) | 0.22 | 0.14 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 95.71 | 18.92 |
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.